NATCAPSUQ · NSE
Natural Capsules Limited
₹216.18
+7.35% (+₹14.81)
Prev. close
₹201.37
Volume
32,916
Delivery %
58.7%
As of
02 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Natural Capsules Limited
Natural Capsules Limited engages in the manufacture and sale of hard gelatin and cellulose capsule shells in India and internationally. The company offers bovine spongiform encephalopathy and transmissible spongiform encephalopathy free gelatin, shiny gelatin, sodium lauryl sulfate free gelatin, halal-certified gelatin, fast-release gelatin, printed gelatin/cellulose, vegetarian, and enteric capsule shells. It also provides pharmaceutical dosage forms in capsule dosage form for pharma and neutraceutical products. In addition, the company offers steroidal APIs and derivative salts comprising prednisolone, betamethasone, dexamethasone and hydrocortisone. Natural Capsules Limited was incorporated in 1993 and is based in Bengaluru, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Sunil Laxminarayana Mundra
Headquarters
Bengaluru
Employees
615
Website
naturalcapsules.comExchange
View on NSE ↗Key stats
Market cap
₹236.31 Cr
EPS (TTM)
₹-23.98
Beta (1Y · daily vs NIFTY 50)
0.40
Shares float
36.70 L
EPS · quarter ended Mar 2026
₹-4.82
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (consolidated), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 4.6% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide. EBITDA is omitted from this chart: coverage begins inside the plotted window, and every plotted period must carry a complete point set — the P&L table below has the available figures.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹79.51 Cr | ₹135.07 Cr | ₹164.72 Cr | ₹151.29 Cr | ₹169.21 Cr | ₹187.20 Cr | |
| EBITDA | — | — | ₹35.61 Cr | ₹21.85 Cr | ₹18.22 Cr | ₹17.20 L |
| ₹6.91 Cr | ₹13.92 Cr | ₹18.45 Cr | ₹5.55 Cr | ₹61.74 L | ₹-24.66 Cr | |
| Diluted EPS | — | — | ₹19.86 | ₹5.97 | ₹0.63 | ₹-23.84 |
Total expenses (as filed), Employee benefit expense, Depreciation & amortisation, Other expenses, EBITDA, Pretax income, Tax provision, Interest expense, Other income, Diluted EPS have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹97.04 Cr | ₹164.28 Cr | ₹288.76 Cr | ₹376.53 Cr | ₹419.35 Cr | ₹424.16 Cr | |
| — | — | ₹96.79 Cr | ₹109.01 Cr | ₹105.19 Cr | ₹115.48 Cr | |
| Stockholders' equity | ₹62.10 Cr | ₹82.98 Cr | ₹123.23 Cr | ₹203.80 Cr | ₹232.94 Cr | ₹221.64 Cr |
Current assets, Non-current assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹17.22 Cr | ₹-8.35 Cr | ₹26.75 Cr | ₹10.92 Cr | |
| Investing cash flow | — | — | ₹-104.63 Cr | ₹-72.59 Cr | ₹-44.48 Cr | ₹-10.77 Cr |
| — | — | ₹87.49 Cr | ₹81.72 Cr | ₹16.17 Cr | ₹-62.03 L | |
| Capital expenditure | — | — | ₹-105.89 Cr | ₹-71.63 Cr | ₹-44.63 Cr | ₹-11.53 Cr |
| End cash position | — | — | ₹1.48 Cr | ₹2.25 Cr | ₹68.89 L | ₹22.03 L |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt issued, Debt repaid, Dividends paid, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Feb 25 | Mar 25 | Jun 25–Dec 25(3Q) | Mar 26 | Jun 26 |
|---|---|---|---|---|---|
| Promoter | 51.14% | 51.21% | 51.26% | 51.04% | 50.92% |
| Public | 48.86% | 48.79% | 48.74% | 48.96% | 49.08% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,846.4 | 37.1 | 5.37 | 13.7% | 0.06 | +11.9% | +12.3% |
| Divi's Laboratories Limited | ₹2.48 L Cr | ₹9,624 | 84.9 | 14.81 | 15.3% | 0.00 | +12.3% | +59.0% |
| Torrent Pharmaceuticals Limited | ₹1.88 L Cr | ₹4,985 | 78.8 | 22.38 | 25.8% | 1.79 | +21.5% | +36.5% |
| Apollo Hospitals Enterprise Limited | ₹1.28 L Cr | ₹8,835.5 | 61.5 | 13.52 | 20.5% | 0.90 | +15.7% | +14.2% |
| Lenskart Solutions Limited | ₹1.20 L Cr | ₹686.7 | 181.0 | 13.70 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.16 L Cr | ₹1,170.1 | 25.9 | 4.28 | 18.6% | 0.46 | +18.4% | +12.0% |
| Cipla Limited | ₹1.12 L Cr | ₹1,384.1 | 33.2 | 3.25 | 11.3% | 0.02 | +2.1% | -10.3% |
| Laurus Labs Limited | ₹1.09 L Cr | ₹2,034 | 99.7 | 20.52 | 16.8% | 0.48 | +22.0% | +123.5% |
| Max Healthcare Institute Limited | ₹1.02 L Cr | ₹1,066.6 | 70.4 | 9.50 | 13.4% | 0.32 | +19.0% | -8.0% |
| Dr. Reddy's Laboratories Limited | ₹1.01 L Cr | ₹1,211.2 | 30.5 | 2.68 | 11.4% | 0.21 | +3.2% | -7.4% |
| Manipal Health Enterprises Limited | ₹99,126.82 Cr | ₹760.95 | 150.7 | 11.76 | 7.8% | 1.53 | +18.0% | — |
| Natural Capsules Limited | ₹236.31 Cr | ₹216.18 | — | 1.07 | -11.1% | 0.52 | +11.5% | -6.9% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 30
Concall transcripts
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.